2022-11-25 10:18:01

Nine valent HPV vaccine; QuotAging& After quota, it has been carried out in three domestic cities; QuotFirst stitch& Quota inoculation

At the fifth Expo, MSD brought its "star product", the world's only 9-valent human papillomavirus vaccine (HPV vaccine), which was the first time that the vaccine appeared at the Expo after it was announced to be "age extended" in China.

In August this year, the 9-valent HPV vaccine produced by MSD was approved by the State Food and Drug Administration, and the applicable population in China has expanded from women aged 16-26 to women aged 9-45. According to MSD, after the 9-valent HPV vaccine was announced to be "age extended" in China, up to now, the first dose of "age extended" HPV vaccine has been carried out in Boao, Hainan, Xi'an, Shaanxi and Jinan, Shandong. Other provinces are also following the relevant process. Next, the "first dose" will be gradually carried out in many cities in China.

Nine valent HPV vaccine; QuotAging& After quota, it has been carried out in three domestic cities; QuotFirst stitch& Quota inoculation



It is understood that there are three high-risk HPV subtypes most susceptible to infection among Chinese women, and the infection rate is distributed as a "double peak" according to age: the first peak is "17-24 years old", and the second peak is "40-44 years old". After the age of the nine valent vaccine is extended, the applicable age covers 9-15 years old and 27-45 years old, which can prevent 92% of cervical cancer and 90% of genital warts..